Tudca (Tauroursodeoxycholic Acid) for Eye Health

Research suggests that TUDCA shows consistent promise as a neuroprotective and anti-inflammatory agent for several eye conditions, with published studies and reviews pointing to potential benefits across retinal diseases, corneal injury, and photoreceptor preservation. The available evidence includes in vitro and animal model studies demonstrating that TUDCA can protect retinal pigment epithelial cells from oxidative stress through autophagy pathways, inhibit inflammation following ocular injury, and support photoreceptor survival in conditions like retinal detachment and diabetic retinopathy. Multiple review articles covering glaucoma, age-related macular degeneration, and other retinal degenerations consistently identify TUDCA and closely related bile acid compounds as strong candidates for further development, and at least one large clinical trial is currently underway examining a closely related compound, UDCA, for visual recovery after retinal detachment. However, the current body of evidence for TUDCA specifically in humans remains limited, as much of the supporting data comes from laboratory and animal research rather than controlled human trials, meaning the translation of these findings to clinical practice has not yet been established.